Microfluidic Fabrication of Peptide/mRNA Complexes for Pulmonary Delivery: Technical Advances and Implications

Study Background and Research Question

Messenger RNA (mRNA) and small interfering RNA (siRNA) are emerging as transformative modalities for treating a spectrum of lung diseases, including asthma, chronic obstructive pulmonary disease, and cystic fibrosis. Their ability to modulate gene expression directly within the pulmonary epithelium offers unique therapeutic potential. However, the delivery of these hydrophilic, negatively charged macromolecules is hampered by susceptibility to degradation and the need for efficient cellular uptake. Traditional non-viral vectors such as lipid nanoparticles (LNPs) have shown success in systemic administration, but their stability and transfection efficacy are challenged under the physical stresses of pulmonary delivery routes, particularly nebulisation. This context sets the stage for the study by Ma et al. (2025), which addresses the critical question: Can non-viral peptide-based RNA delivery systems, fabricated via microfluidic mixing, reliably withstand nebulisation and achieve effective mRNA transfection in lung epithelial cells?

Key Innovation from the Reference Study

The primary innovation lies in the application of microfluidic mixing to generate peptide/RNA complexes with high reproducibility and control over particle characteristics. This approach allowed the authors to prepare complexes of mRNA or siRNA with two distinct cationic peptides, LAH4-L1 and PEG12KL4, in a manner compatible with subsequent aerosolisation via vibrating mesh nebulisers. The critical advance is the demonstration that such complexes, even after experiencing the mechanical and interfacial stresses of nebulisation, retain both their structural integrity and biological function—namely, RNA binding and transfection capability—according to the reference study.

Methods and Experimental Design Insights

The study utilised a microfluidic mixing protocol to fabricate four types of peptide/RNA complexes: LAH4-L1/siRNA, PEG12KL4/siRNA, LAH4-L1/mRNA, and PEG12KL4/mRNA. This technique ensures precise control over mixing conditions, promoting uniform particle formation and scalability for translational applications. After optimising the complexation process, the resulting particles were subjected to nebulisation using a vibrating mesh device, a clinically relevant method for generating inhalable aerosols. Key physicochemical parameters—including hydrodynamic diameter, RNA binding efficiency, and particle stability—were assessed both before and after nebulisation. The biological performance of these complexes was evaluated through in vitro transfection assays in human lung epithelial cell lines (A549 and BEAS-2B), focusing on post-nebulisation functionality.

Protocol Parameters

• Microfluidic mixing conditions: Peptide and RNA streams combined under controlled flow rates, enabling reproducible particle formation and size distribution.
• Nebulisation: Use of a vibrating mesh nebuliser; output aerosol with mass median aerodynamic diameter <5 μm, suitable for deep lung deposition.
• Particle assessment: Hydrodynamic size measured by dynamic light scattering; binding efficiency evaluated via gel retardation and fluorescence-based assays.
• Transfection efficiency: Quantified in A549 and BEAS-2B cells using standard reporter gene assays post-transfection and post-nebulisation.

Core Findings and Why They Matter

All peptide/RNA complexes retained an inhalable size distribution after nebulisation, with particle diameters reduced to ~100 nm regardless of initial dimensions. Critically, the RNA binding capacity and transfection efficacy of the complexes were not significantly diminished by the stresses of aerosolisation. This preservation of function is essential for the practical deployment of mRNA therapeutics via inhaled routes, as it indicates that microfluidic peptide-based vectors can overcome two major barriers associated with LNPs: instability and functional loss under nebulisation (Ma et al., 2025). The study thus establishes a foundation for further development of inhalable mRNA therapies, with potential applications in both acute and chronic lung conditions.

Comparison with Existing Internal Articles

Recent internal articles have explored the use of 5-methoxyuridine modified mRNA and fluorescently labeled mRNA constructs for delivery analysis in mammalian cells. For example, the article "ARCA Cy5 EGFP mRNA (5-moUTP): Illuminating Intracellular..." discusses how dual-label mRNA tools facilitate quantitative assays of mRNA localization and translation efficiency, and minimize innate immune activation. These insights align with the reference study's emphasis on the importance of vector stability and cell-compatibility, particularly for delivery system research. Furthermore, the internal article "ARCA Cy5 EGFP mRNA (5-moUTP): Advancing mRNA Localization Assays" highlights the integration of fluorescence-based readouts to streamline troubleshooting and quantitative evaluation of transfection workflows. While the reference study focuses on the formulation and aerosolisation aspects, the internal resources emphasize the downstream detection and quantification of mRNA uptake, together offering a comprehensive workflow for mRNA delivery and analysis.

Limitations and Transferability

While the microfluidic mixing approach delivers robust, reproducible complexes with preserved functionality after nebulisation, several limitations should be considered. First, the in vitro assessment in A549 and BEAS-2B cell lines, while informative, may not fully recapitulate the complex environment of the human lung, including airway mucus, surfactants, and immune modulators. Second, the peptides evaluated (LAH4-L1 and PEG12KL4) are synthetic vectors with limited clinical experience compared to LNPs. Third, the study did not directly evaluate the long-term stability of the complexes in storage or under repeated freeze-thaw cycles, which are practical concerns for clinical translation. Finally, the translation from bench to bedside will require rigorous safety, immunogenicity, and efficacy testing in preclinical models and ultimately in humans, as discussed in the reference study. Despite these caveats, the microfluidic peptide/mRNA formulation strategy holds promise for adaptable, patient-friendly pulmonary gene therapies.

Research Support Resources

For researchers aiming to replicate or extend mRNA delivery and localization studies in mammalian cells, standardized tools such as ARCA Cy5 EGFP mRNA (5-moUTP) (SKU R1009) can facilitate assay development. This 5-methoxyuridine modified mRNA construct, fluorescently labeled for direct detection, supports applications in mRNA localization and translation efficiency assays, and is compatible with transfection and immune activation suppression studies. Integrating such reference reagents can streamline the evaluation of new mRNA delivery systems, including peptide-based or microfluidic-fabricated complexes, as highlighted in both the reference study and recent internal literature. These resources enable rigorous benchmarking and visualization of mRNA trafficking and expression in mammalian cell models.